83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through ...
– Nine patients enrolled as of August 5, 2024 across the RESET™ clinical development program, including four since EULAR in June, with 22 U.S. clinical sites now enrolling – – Additional clinical data ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Investing.com - Jefferies has resumed coverage on Cabaletta Bio Inc. (NASDAQ:CABA) with a Buy rating and a $14.00 price target, joining a strong bullish consensus among analysts. According to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results